Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

60P - CCL2 expression and the neutrophil plasma membrane characteristics in blood in different stages of endometrial cancer

Date

06 Oct 2021

Session

e-Posters

Presenters

Tatyana Abakumova

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

T. Abakumova1, S. Gening2, T. Gening2

Author affiliations

  • 1 Ulyanovsk State University, Ulyanovsk/RU
  • 2 Ulyanovsk State University, 432017 - Ulyanovsk/RU
More

Abstract 60P

Background

The mechanisms of neutrophils (Nph) recruitment to a tumor and their pro-tumor polarization are poorly understood. The CCL family of chemokines enhance the tumor recruitment, and the plasma membrane topography affects Nph activity. We aimed to evaluate the CCL2 expression, the stiffness and surface markers expression of Nph plasma membrane in blood in endometrial cancer (EC).

Methods

Blood samples were obtained from the primary endometrioid EC patients, stage I-III FIGO (n=58), uterine myoma patients (n=20) and healthy women (n=30). The CCL2 level was determined by ELISA (JSC Vektor-Best-Volga, Russia). Circulating Nph plasma membrane stiffness was measured by atomic force microscopy (NT-MDT, Russia). The CD16, CD95 Nph surface expression was assessed by fluorescence microscopy. Statistical analysis was performed using Statistica 13.

Results

We observed that serum CCL2 level was decreased in myoma (197.6 (Q1-Q3 147.1-255.1) pg/ml) (p=0.013) and increased in stage I EC (299.6 (255.8-411.8) pg/ml) (p=0.012) compared with the control (270.1 (220.1-310.8) pg/ml). In stage II-III, serum CCL2 level was lower (236.9 (190.2-276.3) pg/ml) than that in stage I (p=0.007). The Nph membrane stiffness in stage I was reduced compared with the control (37.3±2.2 MPa vs 56.7±2.4 MPa) (p=0.051). In stage II-III, the membrane stiffness (70.5±8.4 MPa) was higher than in myoma (p=0.021) and the control (p=0.046). There was a linear regression relationship between serum CCL2 level and Nph membrane stiffness value in stage I (p=0.023), but not in stage II-III. The expression of CD95, a marker involved in immune evasion, was lower in stage II-III compared with myoma (p=0.003) and the control (p=0.006). In EC, membrane stiffness negatively correlated with CD95 expression (r=-0.478, p=0.0005). The number of active mature (CD16+) Nph was lower in stage I compared with myoma (p=0.029) and negatively correlated with serum CCL2 level (r=-0.423, p=0.0024).

Conclusions

The serum CCL2 expression, the structure and marker status of circulating Nph membrane in stage I endometrioid EC differ from those in stage II-III, probably reflecting differences in the Nph recruitment and polarization processes.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.